Spectively. Conclusions: Serum anti-p53 antibody positivity did not predict chemoresistance in
Spectively. Conclusions: Serum anti-p53 antibody positivity did not predict chemoresistance in mCRC treated with fluoropyrimidine, oxaliplatin, plus bevacizumab as first-line chemotherapy. Search phrases: Anti-p53 antibody, KRAS, Metastatic colorectal cancer, First-line…